Fingernail onychomycosis 250 mg PO q24h x6w

Toenail onychomycosis 250 mg PO q24h x12w

Safety and efficacy in pediatric patients have not been established

Hepatic impairment Avoid

CrCl >50CrCl ≤50250 mg PO q24hAvoid

General Information

  • Dermal mycosis

  • Onychomycosis due to dermatophyte

  • Tinea capitis

Perform negative potassium hydroxide (KOH) test and negative culture.

Monitor CBC including differential.

Perform liver function tests at baseline and periodically during therapy.


  • Rash

  • Diarrhea

  • Disorder of taste

  • Indigestion

  • Nausea

  • Vomiting

  • Increased liver enzymes

  • Headache

  • Cough

  • Nasopharyngitis

  • Upper respiratory infection

  • Fever


  • Cutaneous lupus erythematosus

  • Erythema multiforme

  • Generalized exanthematous pustulosis (acute)

  • Stevens-Johnson syndrome

  • Toxic epidermal necrolysis

  • Neutropenic disorder (severe)

  • Thrombotic microangiopathy

  • Liver failure

  • Systemic lupus erythematosus

  • Hearing loss

CYP2D6 inhibitors

Antimicrobial class: Allylamine, Antifungal

Pregnancy category: B

Average serum half life: 36 hours

Precautions: Incidence of liver failure may be increased in patients with serious underlying systemic conditions and severity of hepatic adverse events may be increased with active or chronic liver disease; discontinue if suspected.

Discontinue if taste or smell disturbances are suspected.

Discontinue if serious skin reactions are suspected.

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.